Ironwood Pharmaceuticals, Inc.
http://ironwoodpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ironwood Pharmaceuticals, Inc.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.
Stock Watch: Competitive Wrinkles Mar KalVista, Vertex, Ironwood Trial Successes
It is not ideal to miss the emergence of competition that could reduce your market. Even worse is not to find out that your drug is inferior to generic competition until the end of Phase III.
Ironwood Hits Phase III Endpoint In SBS-IF, But Shareholders Show Wariness
Looking to compete with Takeda’s Gattex in short bowel syndrome with intestinal failure, Ironwood succeeds in a Phase III trial, but investors may be concerned with misses on secondary endpoints.
Asia Deal Watch: Ono Inks Partnerships With Switzerland’s Numab, US Biotech Shattuck
Plus alliances involving Xyphos/Kelonia, Nippon Shinyaku/Vicor, Telix/QSAM, Nicox/Kowa, Kyowa Kirin/BridgeBio, as well as deals in brief.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Microbia, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice